search
Back to results

Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke

Primary Purpose

Ischemic Stroke

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Sildenafil (Viagra)
Usual care
Sponsored by
Henry Ford Health System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ischemic Stroke focused on measuring ischemic stroke, recovery, sildenafil

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with ischemic stroke between 4 and 7 days after symptom onset.
  • Patients age 18-80 years old.
  • NIHSS score of 5-21 prior to treatment (within each cohort, there will be no more than 4 patients with NIHSS < 9 and no fewer than 4 patients with NIHSS > 11).
  • Signed IRB-approved informed consent by patient or authorized representative.

Exclusion Criteria:

General:

  • Participation in another study with an investigational drug or device.
  • Women known to be pregnant, lactating, or of childbearing potential with a positive urine beta-HCG.
  • Patients who cannot receive oral medications.
  • Patients using sildenafil or other phosphodiesterase inhibitors within the previous 7 days of stroke.

Safety Related:

  • Unstable angina.
  • Myocardial infarction within 3 months.
  • Current use of nitrate agents.
  • Current use of alpha-channel antagonists.
  • Current use of medications that inhibit the cytochrome p450 3A4 system. These medications include: amiodarone, aprepitant, bosentan, cimetidine, cisapride, clarithromycin, delavirdine, diltiazem, efavirenz, erythromycin, fluconazole, fluvoxamine, grapefruit juice, imatinib, itraconazole, ketoconazole,loratadine, mibefradil, mifepristone (RU-486), niacin, nefazodone, quinidine, quinine, ritonavir, saquinavir, tacrolimus, verapamil, voriconazole.
  • St. John's Wort and phenytoin (inducers of cytochrome P450 3A4)
  • Baseline systolic blood pressure less than 100 mmHg.
  • Penile deformities.
  • Creatinine > 1.5.
  • Abnormal liver function studies.
  • Patients with a previous history of sudden monocular vision loss Potentially Interfering with Outcomes Assessment:
  • Prior history of dementia.
  • Patients without fixed address or those deemed unlikely to present for follow-up by the investigator.
  • Patients whose life expectancy is less than 90 days.
  • Pre-stroke modified Rankin score > 2.
  • Glucose greater than or equal to 400 mg/dL at presentation.
  • Other serious illness (e.g., severe hepatic, cardiac, or renal failure; acute myocardial infarction; or a complex disease that may confound treatment assessment).
  • Previous stroke or TIA within 30 days.
  • Allergy or hypersensitivity to sildenafil or other phosphodiesterase inhibitors.
  • History of sudden monocular visual disturbance.
  • History of sudden unilateral hearing problem.

Imaging Related:

  • Evidence of primary intraparenchymal hemorrhage on initial neuroimaging study.
  • Neuroimaging evidence of nonvascular cause for the neurological symptoms.

Sites / Locations

  • Henry Ford Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Sildenafil

Usual post-stroke care

Arm Description

Orally administered sildenafil in addition to usual care.

Usual post-stroke treatment including physical, occupational, and speech therapy.

Outcomes

Primary Outcome Measures

The maximum tolerated dose and toxicity profile of sildenafil treatment in patients with subacute ischemic stroke.

Secondary Outcome Measures

The estimated efficacy of sildenafil in comparison with concurrent patients randomized assigned to usual care.

Full Information

First Posted
March 26, 2007
Last Updated
March 15, 2011
Sponsor
Henry Ford Health System
search

1. Study Identification

Unique Protocol Identification Number
NCT00452582
Brief Title
Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke
Official Title
Phase 1 Study of Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke
Study Type
Interventional

2. Study Status

Record Verification Date
March 2011
Overall Recruitment Status
Terminated
Why Stopped
Failure to recruit in expected time period.
Study Start Date
April 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Henry Ford Health System

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Stroke is the third leading cause of death in the United States and the leading cause of serious long-term disability. Approximately 50% of the 750,000 people affected by stroke each year have residual physical impairment. Treatment options for recovery are limited at this time. Sildenafil (Viagra) has demonstrated the capability of significantly improving recovery in several animal experiments of stroke. This study is aiming to establish the safety of treatment with sildenafil in people with stroke with the ultimate aim of testing its usefulness to improve recovery.
Detailed Description
Stroke is the third leading cause of death and the leading cause of serious long-term disability in the United States. Approximately 15-30% of stroke survivors are permanently disabled. Twenty eight percent of stroke patients are under age 65 which results in a loss of work income. While many restorative therapies are touted as promising for the treatment of ischemic stroke, to date none are approved for this purpose. Sildenafil (Viagra®), a phosphodiesterase type 5 inhibitor, has been shown to reduce mortality and improve the functional outcomes of young and aged rats when administered 24 hours and 7 days after stroke onset. Such results are encouraging and warrant further investigation in human stroke. The specific aims of this study are to assess the safety of treating ischemic stroke patients with sildenafil (Viagra®) and to evaluate their outcomes at day 90. This will be a phase I dose-escalation study with cohort sizes of 12 patients (depending on the occurrence of serious adverse events). A total enrollment of 120 patients is planned. Patients who are between 4 and 7 days from stroke onset will receive 25, 50, 75, 100, 125, 150, 175, and 200 mg daily of sildenafil for a period of 14 days. Of the 120 patients, 24 will be randomly selected to receive standard treatment but will not receive sildenafil. All patients and physicians will be aware of treatment assignment. Evaluation of potential toxicity will be monitored throughout the course of treatment and during a formal visit at day 16 after initiation of treatment. Plasma monitoring of vascular endothelial growth factor (VEGF) will be made prior to treatment, at days 7, 16, 30, 60, and 90. Measurements of NIHSS scores, Rankin scores, and Barthel indices will be made at days 30, 60, and 90. Patients will also be assessed for color vision changes and sexual function during day 16 and day 90 visits. There will be every other day phone calls to patients while on treatment. The primary outcome measure will be death, recurrent stroke, and myocardial infarction during treatment. Exploratory analysis will include functional outcomes as measured on the neurological scales, and changes in VEGF levels in relation to clinical outcome. The long-term objective is to identify a safe and easily administered treatment that improves functional outcome in patients with ischemic stroke.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Stroke
Keywords
ischemic stroke, recovery, sildenafil

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sildenafil
Arm Type
Experimental
Arm Description
Orally administered sildenafil in addition to usual care.
Arm Title
Usual post-stroke care
Arm Type
Active Comparator
Arm Description
Usual post-stroke treatment including physical, occupational, and speech therapy.
Intervention Type
Drug
Intervention Name(s)
Sildenafil (Viagra)
Intervention Description
Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
Intervention Type
Other
Intervention Name(s)
Usual care
Intervention Description
Physical therapy, occupational therapy, speech therapy
Primary Outcome Measure Information:
Title
The maximum tolerated dose and toxicity profile of sildenafil treatment in patients with subacute ischemic stroke.
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
The estimated efficacy of sildenafil in comparison with concurrent patients randomized assigned to usual care.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with ischemic stroke between 4 and 7 days after symptom onset. Patients age 18-80 years old. NIHSS score of 5-21 prior to treatment (within each cohort, there will be no more than 4 patients with NIHSS < 9 and no fewer than 4 patients with NIHSS > 11). Signed IRB-approved informed consent by patient or authorized representative. Exclusion Criteria: General: Participation in another study with an investigational drug or device. Women known to be pregnant, lactating, or of childbearing potential with a positive urine beta-HCG. Patients who cannot receive oral medications. Patients using sildenafil or other phosphodiesterase inhibitors within the previous 7 days of stroke. Safety Related: Unstable angina. Myocardial infarction within 3 months. Current use of nitrate agents. Current use of alpha-channel antagonists. Current use of medications that inhibit the cytochrome p450 3A4 system. These medications include: amiodarone, aprepitant, bosentan, cimetidine, cisapride, clarithromycin, delavirdine, diltiazem, efavirenz, erythromycin, fluconazole, fluvoxamine, grapefruit juice, imatinib, itraconazole, ketoconazole,loratadine, mibefradil, mifepristone (RU-486), niacin, nefazodone, quinidine, quinine, ritonavir, saquinavir, tacrolimus, verapamil, voriconazole. St. John's Wort and phenytoin (inducers of cytochrome P450 3A4) Baseline systolic blood pressure less than 100 mmHg. Penile deformities. Creatinine > 1.5. Abnormal liver function studies. Patients with a previous history of sudden monocular vision loss Potentially Interfering with Outcomes Assessment: Prior history of dementia. Patients without fixed address or those deemed unlikely to present for follow-up by the investigator. Patients whose life expectancy is less than 90 days. Pre-stroke modified Rankin score > 2. Glucose greater than or equal to 400 mg/dL at presentation. Other serious illness (e.g., severe hepatic, cardiac, or renal failure; acute myocardial infarction; or a complex disease that may confound treatment assessment). Previous stroke or TIA within 30 days. Allergy or hypersensitivity to sildenafil or other phosphodiesterase inhibitors. History of sudden monocular visual disturbance. History of sudden unilateral hearing problem. Imaging Related: Evidence of primary intraparenchymal hemorrhage on initial neuroimaging study. Neuroimaging evidence of nonvascular cause for the neurological symptoms.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brian Silver, MD
Organizational Affiliation
Henry Ford Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
19717023
Citation
Silver B, McCarthy S, Lu M, Mitsias P, Russman AN, Katramados A, Morris DC, Lewandowski CA, Chopp M. Sildenafil treatment of subacute ischemic stroke: a safety study at 25-mg daily for 2 weeks. J Stroke Cerebrovasc Dis. 2009 Sep-Oct;18(5):381-3. doi: 10.1016/j.jstrokecerebrovasdis.2009.01.007.
Results Reference
result

Learn more about this trial

Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke

We'll reach out to this number within 24 hrs